Brief: Taiho Oncology, Taiho Pharmaceutical And Cullinan Therapeutics initiate rolling submission of new drug application to US FDA
20/11/2025 12:20
Nov 20 (Reuters) - Cullinan Therapeutics Inc CGEM.O: TAIHO ONCOLOGY, TAIHO PHARMACEUTICAL AND CULLINAN THERAPEUTICS INITIATE ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ZIPALERTINIB FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS TAIHO ONCOLOGY INC: ANTICIPATE COMPLETION OF NDA SUBMISSION IN Q1 2026 WITH ASSOCIATED REQUEST FOR PRIORITY REVIEW Source text: nPn5Pksx3a Further company coverage: CGEM.O ((Reuters.Briefs@thomsonreuters.com;))